RETATRUTIDE

Retatrutide (Reta) — An investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. It is being studied for weight management, appetite regulation, and metabolic health. Unlike tirzepatide, retatrutide is not currently FDA-approved.